Pharma

Your Article Summary

See Latest Articles

Lonza and Teva Announce Receipt of Regulatory Approval
Teva Pharmaceutical Industries, 05/15/09

Teva Pharmaceutical Industries Ltd. and Lonza Group Ltd. announced that the European Commission granted antitrust approval to the joint venture between the two companies, which was originally announced on January 2009. In their joint venture Teva and Lonza will cooperate to develop, manufacture and market a number of affordable, efficacious and safe generic equivalents of a selected portfolio of biologic pharmaceuticals.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09

Safety concerns slow new drug review and approval processes
Formulary , 12/02/09

Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09

 See all of Drug/Product Approvals